Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Release Date: March 31, 2021
Expiration Date: March 31, 2022
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, Dr. Baljevic discusses patients with newly diagnosed multiple myeloma who are eligible for transplant and reviews recent data from trials evaluating novel multi-drug combinations in the frontline setting. He also identifies the management of treatment-emergent adverse events that are associated with different treatment approaches.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Choose optimal therapeutic regimens based on specific patient- and disease-related characteristics
- Employ current guidelines and evolving data from trials evaluating novel multi-drug combinations in the frontline setting
- Identify and manage treatment-emergent adverse events associated with treatment approaches in the frontline setting
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy? –Muhamed Baljevic, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 31, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Muhamed Baljevic, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Dr. Muhamed Baljevic completed his medical education at the Weill Cornell Medical College. During his medical training, he worked in the Ansary Center for Stem Cell Therapeutics at the Weill Cornell Medical College of Cornell University. He subsequently completed his internal medicine internship and residency at New York-Presbyterian Hospital Weill Cornell Medical Center, and his hematology and medical oncology training at The University of Texas MD Anderson Cancer Center. In addition, Dr. Baljevic pursued a master’s degree in clinical and translational research at The University of Texas Graduate School of Biomedical Sciences. Dr. Baljevic is Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Internal Medicine at the University of Nebraska Medical Center (UNMC), where he also works as a plasma cell dyscrasia (PCD) specialist, transplanter, and clinical/translational trialist at Fred & Pamela Buffet Cancer Center (FPBCC).Dr. Baljevic is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology, the American Association for Cancer Research (AACR), the European Hematology Association, and the American Society of Transplantation and Cellular Therapy. In addition, he is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel, as well as the Myeloma CAR T cell strategic council. Dr. Baljevic serves on the editorial board for Frontiers in Oncology. He also has contributed to publications in Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Circulation Research, Hematology/Oncology Clinics of North America, as well as several book chapters.
In his current role at FPBCC, Dr. Baljevic investigates early-phase development of pre-clinical concepts in post-transplant immune reconstitution in an effort to obtain a better understanding of proteasome inhibitor resistance. His research also seeks to identify novel approaches for the treatment of B-cell and myeloid malignancies, including novel immunotherapy, antibody conjugates, CAR T cells, BiTEs, and small molecule targeted inhibitors. He recently successfully performed the first bloodless stem cell transplantation for a Jehovah’s Witness multiple myeloma patient in the state of Nebraska.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-015-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Muhamed Baljevic has received honoraria related to formal advisory activities and as a consultant from Bristol-Myers Squibb Company and Celgene Corporation – A Bristol-Myers Squibb Company. He has received grant support related to research activities from Karyopharm Therapeutics.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Lillian McVey, Medical Writer, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.